C
hronic obstructive pulmonary disease (COPD) is characterized by partially reversible chronic airflow obstruction caused by an abnormal inflammatory reaction in the airways and lung parenchyma to inhaled toxins, most notably cigarette smoke. 1. 2 The clinical course is marked by a slow progressive decline in lung function, considered to be the stable phase of the disease, with episodic acute exacerbations presenting as an increase in dyspnea, cough, and/or sputum production. 1,a Exacerbations requiring hospitalization are associated with 3% to 4% short-term mortality? Half of those patients hospitalized will be readmitted at least once over the next 6 months, a Chronic obstructive pulmonary disease is the fourth leading cause of death in the United States . 4 Treatment with inhaled corticosteroids has been shown to reduce local inflammatory cells and systemic markers such as C-reactive protein, improve respiratory symptoms, reduce COPD exacerbations, and slow the progression of lung function decline. 5-9 Anticholinergic bronchodilators inhibit bronchoeonstriction as well as mucus secretion, and have been shown to improve symptoms and reduce exacerbations without producing tolerance to their effects over time. lo-z6 Inhaled anticholinergics are poorly absorbed from the gastrointestinal tract and lung, so that systemic adverse effects are rare. 1 o. 17 ~2-Agonists arc bronchodilators that relax bronchial smooth muscle and are effective in the short-term relief of COPD symptoms. 18 However, long-term use may be associated with tolerance to their effects. 11, 14 We are gradually accumulating evidence concerning the increased risk ~2-agonists have for adverse respiratory and cardiovascular events in patients with asthma and COPD, and are now questioning whether long-acting ~2-agonists such as salmeterol and formoterol should be taken offthe market. [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] Pooled data from 19 randomized controlled trials showed that long-acting ~2-agonists increase hospitalizations for asthma (odds ratio [OR] 2.6, confidence interval [CI] 1.6 to 4.3), lifethreatening asthma exacerbations requiring intubation and ventilation (OR 1.8, CI 1.1 to 2.9} and asthma-related deaths (OR 3.5, CI, 1.3 to 9.3) compared with placebo, a2
The 2 types of bronchodilators, anticholinergics and ~2-agonists, have generally been considered to be equivalent choices for use in patients with COPD. i,a3,34 Despite the fact that anticholinergics have been shown to have equal or superior efficacy compared with ~2-agonists, 15.35-39 surveys have shown that prescriptions for ~2-agonists in COPD are 10 times more common than anticholinergics in the United States and 2 times more common in the United Kingdom and Europe. 4°- 42 The objective of this meta-analysis is to compare the effects of ~2-agonists and anticholinergics on exacerbations requiring ]GIM withdrawal from the trial, severe exacerbations requiring hospitalization, and respiratory deaths in patients with COPD.
MATERIALS AND METHODS

Search Strategy
We performed a comprehensive search of MEDLINE, EMBASE, and Cochrane databases to identify randomized controlled triMs on [~2-agonist or anticholinergic use in patients with COPD, published between 1966 and December 2005. The search was performed using the terms bronchodilator, sympathomimetic, adrenergic ~3-agonist, anticholinergic, cholinergic antagonist, muscarinic antagonist, albuterol, salbutamol, bitolterol, isoetharine, metaproterenol, salmeterol, terbutaline, fenoterol, formoterol, procaterol, isoproterenol, reproterol, eformoterol, bambuterol, ipratropium, tiotropium, or oxitropium and obstructive lung disease, obstructive airway disease, obstructive pulmonary disease, or COPD. Trials were not excluded on the basis of language. The search was augmented by scanning relevant files from the U.S. Food and Drug Administration (FDA) website and references of identified reviews.
Study Selection
Trials were included if they were randomized controlled trials of I32-agonists or anticholinergics compared with placebo or each other, were of at least 3 months duration and reported at least one COPD exacerbation requiring withdrawal from the trial or hospitalization, or any respiratory death. A minimum duration of 3 months was chosen to allow for the development of adverse events. Trials that did not report any included event were excluded from the primary analysis, but were evaluated separately in order to estimate absolute risk differences.
Assessment of Validity
Two reviewers assessed the methodological quality of each trial according to the following factors: (1) Was the randomization procedure adequate and was allocation concealment described?, (2) Were patients and providers blind to the interventions?, (3) Were dropouts and withdrawals reported?, and (4) Was analysis performed by intention-to-treat? Each of these quality domains was scored on a 3-point scale. The quality assessment was used for a sensitivity analysis. 4a '44 
Data Extraction and Synthesis
Two reviewers extracted data from the selected articles, reconciling differences by consensus. In addition, attempts were made to contact the investigators to obtain additional information concerning exacerbations and deaths. The proportion of patients with COPD exacerbations, severe exacerbations, and respiratory deaths from each trial was pooled using the Fixed-effects model, expressed as relative risk (RR) with corresponding 95% confidence intervals. 45 COPD exacerbations were those that required withdrawal from the study or hospitalization. Severe exacerbations were those requiring hospitalization. A respiratory death was defined as a death thought to be due to a lower respiratory tract event, such as a COPD exacerbation, pneumonia, or respiratory failure. Deaths thought to be due to a cardiorespiratory cause were included, if they were thought to be related to the underlying COPD. To test for interstudy heterogeneity, the chi-square value was calculated for the hypothesis of homogeneity, with statistical significant set at ct =0.1. The fixed-effects model was chosen as minimal heterogeneity was noted in the analyses.
Results were reported separately for placebo-controlled trials of anticholinergics and [32-agonists, and for trials comparing I32-agonists to anticholinergics. The analysis was performed using Cochrane Review Manager 4.2 (Cochrane Library Software, Oxford, UK). Only trials that reported at least 1 event were used in the estimation of RR. If more than 1 event occurred in the same patient, only the first event was counted. In a separate analysis, those trials that reported no respiratory deaths were evaluated in order to estimate an absolute risk difference. The number needed to treat (NNT) to prevent an event, and the number needed to harm (NNH) to cause an event, were calculated.
Role of the Funding Source
The funding for this analysis came from salary support for Dr. Salpeter. The institution had no role in the design, conduct, or reporting of the study. The investigators all had complete access to the data, and no sponsorship from the institution or the pharmaceutical industry was provided to conduct this analysis. Figure 1 shows the results of the search for articles. The MED-LINE search identified approximately 5,000 articles, of which 84 were potentially relevant trials of bronchodilator use in COPD. After scanning references from selected articles and the FDA website, an additional 4 trials were identified. The EMBASE and Cochrane databases provided no additional trials, Of these 88 trials, 22 met the inclusion criteria. 12.13. [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] Trials were excluded for the following reasons: 37 trials were of less than 3 months duration, 9 trials did not provide adequate information on exacerbations or respiratory deaths, 2 trials did not compare the 2 types of bronchodilators with placebo or each other, 4 trials were not randomized, 2 trials provided data for asthma and COPD combined, and 12 trials provided data on participants from other trials.
RESULTS
Search Results
Trial Characteristics
The analysis included 22 trials, with a total of 15,276 participants followed for 25,460 patient-years / Table 1 ). The mean trial duration was 20 months (range 3 to 60 months), with a mean study size of 694 participants (62 to 3,923}. The mean (SD) age of participants at baseline was 59.9 (7.7) years in the anticholinergic group, 63.5 (1.01 in the I32-agonist group and 59.6 (7.4) years in the placebo group. The dropout rate was 18.5% in the anticholinergic group, 19.0% in the 132-agonist group and 24.8% in the placebo group. From the available data, concomitant corticosteroids were used in 58.3% of the anticholinergic group, 56.5% of the ~12-agonist group and 57.4% of the placebo group. ~2-agonists used in the trials were albuterol, metaproterenol, formoterol, and salmeterol. Anticholinergic agents studied were ipratropium and tiotropium. 
Methodological Quality of Included Studies
All trials were randomized, double blind trials that performed analysis according to intention-to-treat and adequately described withdrawals. Thirteen trials described the method of randomization or allocation concealment, while 9 did not. No trial received the lowest quality score on any domain, so no sensitivity analysis was performed.
Quantitative Data Synthesis
Anticholinergics Compared with Placebo. Seven trials compared inhaled anticholinergies with placebo ( Fig. 2) . Anticholinergics reduced the risk of a COPD exacerbation requiring withdrawal from the trial by 40% (RR 0.60, CI 0.48 to 0.75) and a severe exacerbation requiring hospitalization by 33% (RR 0.67, CI 0.53 to 0.86). The absolute risk reduction for severe exacerbations was approximately 4 cases per 100 patient-years of treatment compared with placebo, with a NNT of 25. The Lung Health Study 4z provided data on hospitalization for lower respiratory morbidity but not COPD exacerbations, so these were not included in the analysis. If data on lower respiratory morbidity were included as COPD exacerbations, the RR for hospitalization would be 0.75 (CI 0.61 to 0.93).
There were 2 reported respiratory deaths out of 4,036 participants in the anticholinergic group and 12 respiratory deaths out of 3,845 participants in the placebo group, with a reduction in risk of 73% (RR 0.27, CI 0.09 to 0.81). In order to assess absolute rates for respiratory deaths we included those trials that reported no deaths, thus adding to the denominator. The absolute risk reduction for respiratory deaths with anticholinergics was 0.36% per year (NNT of 278).
[12-Agonists Compared with Placebo. There were 13 trials that compared ~12-agonist use with placebo (Fig. 3) . All of the trials except for one 55 evaluated the long-acting ~2-agonists salmeterol and formoterol. Of note, all trials allowed for as-needed 132-agonist use in both the treatment and placebo groups, so in effect were comparing regular ~2-agonist use with as-needed use. Concomitant inhaled eorticosteroids were used in 57% of participants.
The risk of withdrawal from the trial for COPD exacerbation was reduced by 19% (RR 0.81, CI 0.68 to 0.95), without a significant effect on hospitalization (RR 1.08, CI, 0.61 to 1.95). However, ~2-agonist use was associated with a significant increase in respiratory deaths (RR 2.47, CI 1.12 to 5.45) compared with placebo, with 21 deaths out of 1,320 participants in the ~2-agonist group and 8 deaths out of 1,084 participants in the placebo group. When trials without respiratory deaths were included in the analysis, thus adding to the denominator, the absolute risk increase with l~2-agonists is 0.76% per year [NNH of 131).
One trial 66 provided 60% of the weight for respiratory deaths, with data provided from unpublished information and a published erratum. 67 This trial also studied combined treatment with budesonide plus formoterol and budesonide treatment alone, and reported 5 deaths out of 254 patients in the combined treatment group and 6 deaths out of 257 patients in the budesonide group (RR 0.84, CI, 0.26 to 2.73, P=.78).
p2-Agonists Compared with Anticholinergics. Seven trials directly compared ~2-agonists with anticholinergics (Fig. 4) Table I ( 
Analysis of Interstudy Variance and Publication Bias.
No evidence of significant heterogeneity was noted in any of the analyses, P> .3. Funnel plots of effect size versus standard error found no evidence for publication bias in the analysis.
DISCUSSION
Pooled results from 22 randomized trials of patients with COPD show that anticholinergics reduced severe exacerbations by 33% and respiratory deaths by 73% compared with placebo, while 112-agonists resulted in a 2-fold increase in respiratory deaths. The absolute risk reduction for respiratory deaths associated with anticholinergics is 0.36% per year [NNT of 278) and the absolute risk increase associated with [32-agonists is 0.76% per year (NNH of 131). The addition of a 112-agonist to an anticholinergic agent did not improve clinical outcomes. These results suggest that anticholinergics should be the bronchodilator of choice in COPD.
In order to put the risks of 112-agonists into perspective we must also understand the benefits. Pooled data from randomized trials have shown that 112-agonists are effective bronchodilators in patients with COPD, with some trials showing an improvement in symptom scores.IS'68 This meta-analysis indicates that [32-agonists can reduce withdrawals for symptomatic exacerbations by almost 20%.
However, this improvement in symptoms may occur at the same time as a worsening of disease control, manifested by an increase in respiratory mortality. Tolerance to the bronchodilator effect of 112-agonists has been documented in patients with COPD over time, with a significant decline in strength of bronchodilation after 3 months of treatment compared with the first dose. 11-13'15'16'52'54 Evidence of tolerance to the bronchoprotective effect of 112-agonist use in COPD has also been demonstrated, with an increase in bronchial hyperresponsiveness seen with regular treatment, t4
This meta-analysis shows that the anticholinergics, ipratropium and the newer long-acting tiotropium, reduced severe exacerbations and respiratory mortality compared with placebo. Unfortunately, in the United States only 5% of all prescriptions for COPD are anticholinergics. 4° Tiotropium has been shown to prevent the decline in trough FEV1 values that are seen with placebo use over the course of 1 year. 5° '5] . 69 effectiveness analysis found that costs associated with tiotropium are slightly higher than with ipratropium, but that the reduction in hospitalization is thought to be cost-effective. 71 Current guidelines recommend that an inhaled bronchodilator (anticholinergic or [~2-agonist) be used in the treatment of stable COPD, and if symptoms persist or there are frequent exacerbations the addition of an inhaled corticosteroid should be considered, aa In this meta-analysis approximately one-half of the patients treated with J32-agonists had concomitant in- 49 58 62 haled corticosteroid use. Three trials ' • provided data with and without inhaled corticosteroids, but only 1 provided information on severe exacerbations or respiratory deaths, 66 so subgroup analysis on the effect of concomitant inhaled corticosteroids could not be done.
This analysis has several limitations. Standard meta-analytic results can be uncertain when the numbers of events per study are small, as is the case with deaths. Some of the analyses in this study provided pooled data from only 2 trials, so may not provide meaningful results. There was not enough information available to assess the potential protective effect of concomitant inhaled corticosteroids on the adverse effects of [~2-agonists, or the difference in results for long-acting and short-acting [~2-agonists. The search revealed 9 trials that were excluded because no severe exacerbations or deaths were reported. It is difficult to tell if events occurred but were not reported. Other trials did not provide cause of death, so could not be included in the analysis of respiratory deaths. The accurate assessment of respiratory deaths was further hindered by the difficulty in ascertaining the true cause of death. For example, it is possible that the increase in respiratory deaths seen with ~2-agonists may be due in part to an increase in cardiovascular risk. a° Finally, it is unfortunate that no true placebo-controlled trials of J32-agonist use in COPD have been published. Despite these limitations, we believe that this metaanalysis provides valuable information on the comparative effects of anticholinergics and [~2-agonists on clinical outcomes in COPD.
In summary, both anticholinergics and ~2-agonists may be effective bronchodilators and improve symptoms in patients with COPD. Anticholinergics reduced severe exacerbations and respiratory deaths in patients with COPD. However, Jt2-agonists had no effect on severe exacerbations and resulted in an increased rate of respiratory deaths, possibly owing to a reduction in disease control. Concomitant corticosteroids were used in over one-half of patients treated with ~2-agonists, but it is not clear if this provided some protection against the adverse effects. The results of this recta-analysis suggest that anticholinergics should be the bronchodilator of choice in patients with COPD. The long-term safety of J32-agonists in patients with COPD should be addressed.
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